|Bid||0.0000 x 0|
|Ask||0.0000 x 0|
|Day's Range||0.0361 - 0.0436|
|52 Week Range||0.0200 - 0.2050|
|Beta (5Y Monthly)||0.78|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Arrangement is expected to fund Skye's proprietary synthetic cannabinoid-derivative therapeutic initially targeting glaucoma for first Phase 2 clinical study planned to start later in 2022Preclinical studies have demonstrated potential advantages of Skye's unique, patent-protected therapeutic drug, SBI-100 Ophthalmic Emulsion, compared to the standard of careVancouver, British Columbia--(Newsfile Corp. - May 12, 2022) - Emerald Health Therapeutics, Inc. (CSE: EMH) (OTCQB: EMHTF) ("Emerald") and
Vancouver, British Columbia--(Newsfile Corp. - May 6, 2022) - Emerald Health Therapeutics, Inc. (CSE: EMH) (OTCQB: EMHTF) ("Emerald" or the "Company") announced today that it has transferred its US listing to the OTCQB after receiving notice from the OTC Markets Group that the Company no longer meets the listing requirements for continued listing on the OTCQX International tier.On November 3, 2021, Emerald received notice that the Company's bid price had closed below $0.10 for ...
Vancouver, British Columbia--(Newsfile Corp. - April 28, 2022) - Emerald Health Therapeutics, Inc. (CSE: EMH) (OTCQX: EMHTF) ("Emerald" or the "Company") reports that it anticipates it will be unable to file its Annual Filings before the May 2, 2022 deadline and has applied to the British Columbia Securities Commission for a temporary management cease trade order.Under the provisions of Parts 4 and 5 of National Instrument 51-102 - Continuous Disclosure Obligations ("NI 51-102"), Emerald is ...